Form SCHEDULE 13G/A Scinai Immunotherapeutic Filed by: STONE DANIEL E.

February 17, 2026 1:14 PM EST





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 13,872,899,584 ordinary shares outstanding as of December 31, 2025, as disclosed by the issuer on February 15, 2026. Includes 107,000 American Depositary Shares (ADSs) held directly by the Reporting Person, 200,000 ADSs held by RK Stone Miami, LLC ("RK") and 37,867 ADSs issuable upon exercise of pre-funded warrants held by RK. On September 22, 2025, RK exercised 200,000 warrants. As of December 31, 2025, RK holds 200,000 ADSs and 283,426 ADS pre-funded warrants, which may not be exercised if such exercise would result in beneficial ownership by RK, together with its affiliates (which include the Reporting Person) and certain other persons, of greater than 9.99% of the ordinary shares. As disclosed in the Schedule 13G amendment filed with the Securities and Exchange Commission on January 24, 2025, future issuances of ordinary shares or ADSs by the issuer to third parties are expected to cause additional amounts of pre-funded warrants to become exercisable within the foregoing limitation, without increasing the reporting person's beneficial ownership percentage.


SCHEDULE 13G



 
STONE DANIEL E.
 
Signature:/s/ Daniel E. Stone
Name/Title:Stone Daniel E.
Date:02/13/2026
 
RK Stone Miami, LLC
 
Signature:/s/ Daniel E. Stone
Name/Title:Sole Member - RK Stone Miami, LLC
Date:02/13/2026


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

13G